UPLYFT For Lymphoma Survivors

Lymphoma Clinical Trial

Official title: An Intervention for Fear of Cancer Recurrence for Lymphoma Survivors

Status Recruiting

Clinical Trial Summary

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.

Clinical Trial Description

This is a two phase pilot study to develop and pilot the UPLYFT (Understand and Prevail:

Lymphoma Fear of Recurrence Therapy) program intervention that includes lymphoma survivorship information and acceptance and commitment therapy strategies to alleviate fear of cancer recurrence, reduce distress, and improve quality of life among lymphoma survivors.

Phase 1 will be a two-part development process of the UPLYFT program based on interview feedback from lymphoma and mental health clinicians and then feedback from a six-person group of lymphoma survivors after participation in an UPLYFT program field test. Phase 2 is a randomized pilot study using the UPLFYT program finalized in Phase 1.

Research procedures include:

• In depth interview (lymphoma and mental health clinicians)

• Screening for eligibility

• 6 weekly intervention sessions (lymphoma survivors)

• Baseline Assessments and Questionnaires (lymphoma survivors)

74 people are expected to participate in this study with 14 in Phase 1 and 60 in Phase 2.

The American Society of Hematology is providing funding for the trial. ;

Related Conditions & MeSH terms

• Lymphoma
• Survivorship

• NCT number: NCT05080166
• Study type: Interventional
• Source: Dana-Farber Cancer Institute
• Contact: Oreofe O Odejide, MD, MPH
• Phone: (617) 632-6864
• Email: Oreofe_Odejide@dfci.harvard.edu
• Status: Recruiting
• Phase: N/A
• Start date: February 8, 2022
• Completion date: April 30, 2025